Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms.
about
Hepatitis C virus protease inhibitor-resistance mutations: our experience and reviewViral kinetic modeling: state of the artIdentification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohortImpact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agentsInducible protein-10 as a predictive marker of antiviral hepatitis C treatment: A systematic review.Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients.Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis.Evaluation of IL-28B polymorphisms and serum IP-10 in hepatitis C infected chimpanzees.Gene expression profiling to predict and assess the consequences of therapy-induced virus eradication in chronic hepatitis C virus infection.Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infectionIL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B.Interferon γ-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune response.Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infectionImpact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis.Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease.Characterization of the Interleukin-28B Gene rs12979860 C/T Polymorphism in Turkish Chronic Hepatitis C Patients and Healthy Individuals.The Correlation of Il28B Genotype With Sustained Virologic Response In Romanian patients With Chronic Hepatitis C.Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.Tryptophan Breakdown in Patients with HCV Infection is Influenced by IL28B Polymorphism.The correlation between pretreatment cytokine expression patterns in peripheral blood mononuclear cells with chronic hepatitis C outcome.Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?Association of IL28B SNP With Progression of Egyptian HCV Genotype 4 Patients to End Stage Liver Disease.Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 InfectionCorrelations of IFN-γ-inducible protein-10 with the risk of chronic hepatitis B and the efficacy of interferon therapy in Asians.Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection.The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis CTwo IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C in different racial populations: A meta-analysis.Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin.HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV.Genetic predictors of the response to the treatment of hepatitis C virus infection.IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patientsHigh MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activityImpaired toll-like receptor 3-mediated immune responses from macrophages of patients chronically infected with hepatitis C virus.Pharmacogenomics of hepatitis C infections: personalizing therapy.Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?Association of IL28B Genotypes and Baseline Serum Interferon-γ-Inducible- Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China.Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection.Impact of Interleukin 28B Genotype on the Virological Responses in Chronic Hepatitis C Treatment.Impact of Il28b-related single nucleotide polymorphisms on liver transient elastography in chronic hepatitis C infection.
P2860
Q24628717-8282C822-9FB0-4812-B975-EA68294DFA23Q26824655-22C010DD-E401-47D5-8686-2581D6C95691Q28478435-A7602506-FB73-4B03-ADF3-F654C3C5852CQ28732828-1AFD1E88-726D-4C53-B254-FCE3123B6E07Q30365599-C2B68E6D-3E6B-4DD7-8E52-C3EF5E2A9683Q33706737-6E18F0FC-9619-4237-8B81-2F5BB5503F58Q34103218-D8DE84D7-5CC6-4CFB-A98D-202C95966181Q34429833-CD84C94A-6571-4FDD-B9E9-2765839DBDB8Q34464406-20222A49-AA1D-4424-B354-A4C0339501CFQ34593704-0042FF73-6126-4612-92B7-384659D9F469Q34599847-514ADAE9-5C2E-4AC1-8A27-BC8DFE1C1400Q34612816-EEB43D83-46A2-47B8-A090-70B270E0AC05Q34974790-ACA4355A-1062-4D2E-BE7D-C81F03C9FAC6Q35053399-9E351C4C-CBE7-4F6E-A810-3353866B58E7Q35122925-8459893B-C856-4526-8D75-284AFDA76236Q35197060-E240578D-55F0-4072-B60F-4D85FC168EE9Q35609162-A1A1C3CC-2888-472B-B94A-646FA06EB6E4Q35764210-0F0E8DC5-2370-4D90-9C6E-F40CC3B7C9D6Q35764450-1D2996EB-6DA2-435B-9232-7ED375D7E5DBQ35818383-F557B3EF-4DD7-4E9A-9498-6B5038FE8757Q35861413-C6637527-E89B-459E-A44B-CC55AB51758BQ35947900-E2B8E45D-C7DF-4176-9A38-F3B883989024Q35990084-2D54B406-39E9-47A3-8E2E-F25D0618FDAEQ36014286-2D5465BC-49C1-40A4-A524-AF8B187565A9Q36014403-0126BC83-CD8D-4C29-B773-CFFD3CB58B29Q36109002-5DC66333-1478-4D5F-AB1F-9D04E072E043Q36208380-29CB9EB9-955C-48C3-B2AB-0EE541DAB954Q36224697-9B99F6AA-B614-4ECA-8A4D-532B3EB6D8B7Q36246785-38CD9580-82B3-4131-8358-DE201D68CA40Q36399139-7594E582-1E9D-4DB3-9B5C-53F3E8EEF8F4Q36402309-11B350FD-9974-4884-A9D6-7F1F61A01977Q36541206-3B64FED9-207D-415E-A02C-A825A469AAFFQ36554751-1B955D73-6D92-4D2D-9BCC-5D3BD00FB38DQ36606736-4DDD579D-F2F7-46F9-804E-0F75552FA416Q36632938-08DDC407-1BE7-4E19-8DAF-46FEB69247E9Q36810400-E069EF37-3F7E-4AD4-AD7E-605CB4473282Q36848968-2D29AD49-2079-4E15-B8C4-16786FEE6144Q36874661-A6A8E172-2653-4C9D-B891-81A4D5147817Q37292899-820B727A-7D52-4462-9CD7-42DCCFFA2D81Q37308845-380887AC-9C45-492D-A88B-2CBD8F23C408
P2860
Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Response prediction in chronic ...... ngle nucleotide polymorphisms.
@ast
Response prediction in chronic ...... ngle nucleotide polymorphisms.
@en
type
label
Response prediction in chronic ...... ngle nucleotide polymorphisms.
@ast
Response prediction in chronic ...... ngle nucleotide polymorphisms.
@en
prefLabel
Response prediction in chronic ...... ngle nucleotide polymorphisms.
@ast
Response prediction in chronic ...... ngle nucleotide polymorphisms.
@en
P2093
P2860
P50
P1433
P1476
Response prediction in chronic ...... ngle nucleotide polymorphisms.
@en
P2093
Ana Romero
Avidan U Neumann
DITTO-HCV Study Group
Francesco Negro
Galia Askarieh
Johan Westin
Jonas Söderholm
Magnus Lindh
P2860
P304
P356
10.1371/JOURNAL.PONE.0017232
P407
P50
P577
2011-02-24T00:00:00Z